

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED

Representative: Joji Nakayama, President and CEO

(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)

Please address inquiries to Toshiaki Sai, Corporate Officer,

Vice President, Corporate Communications Department

Telephone: +81-3-6225-1126

<http://www.daiichisankyo.com/>

TOKYO, Japan (December 7, 2011) – Today, some media in Japan reported that Daiichi Sankyo Co., Ltd. and GlaxoSmithKline plc will establish a vaccine-related joint venture company .

Our company consider vaccines to be a core business segment, and to strengthen our operations we constantly evaluate a wide range of strategic development opportunities.

However, today's media reports are not based on any official announcement by the Daiichi Sankyo Group.

###